|Other names||ISIS-426115; ISIS-GCCRRx|
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported. The drug is an antisense oligonucleotide against the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.
- "IONIS GCCRRx". AdisInsight. Springer Nature Switzerland AG.
- Chikara G, Sharma PK, Dwivedi P, Charan J, Ambwani S, Singh S (April 2018). "A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?". Indian Journal of Clinical Biochemistry. 33 (2): 121–131. doi:10.1007/s12291-017-0668-z. PMC 5891460. PMID 29651202.